Format

Send to

Choose Destination
Eur J Immunol. 2008 Nov;38(11):2957-61. doi: 10.1002/eji.200838833.

Tumor cell recognition by the NK cell activating receptor NKG2D.

Author information

1
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Abstract

Evidence for increased tumor incidence in NKG2D-deficient mice has set NKG2D as the first innate immune receptor implicated in immunosurveillance of tumors. In this viewpoint article, we discuss recent genetic insight into NKG2D-mediated suppression of spontaneous tumor development in the context of NKG2D signaling properties. Moreover, we identify unresolved issues and consider how an understanding of NKG2D-receptor and -ligand biology can facilitate successful therapeutic intervention of human cancer.

PMID:
18979516
DOI:
10.1002/eji.200838833
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center